Physician profile
Lalith Kumar Gande
NPI 1821275082
$1,396.14
in general payments reported to CMS, 2019-2025
26 companies · $410 in 2025
The $410 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $18.27 · 2022: $29.09 · 2023: $555 · 2024: $383 · 2025: $410.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,306 · Education: $42.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,306.28 |
| Education | $42.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $187.24 | 2023-2024 | Xarelto |
| Otsuka America Pharmaceutical, INC. | $167.33 | 2023-2025 | Rexulti |
| Pfizer INC. | $127.22 | 2022-2024 | |
| Optinose US, INC. | $111.73 | 2025 | |
| Nestle Healthcare Nutrition INC. | $104.01 | 2023 | |
| Lundbeck LLC | $76.32 | 2025 | Rexulti |
| Verity Pharmaceuticals INC. | $66.93 | 2024-2025 | Tlando |
| Mannkind Corporation | $59.31 | 2025 | |
| Glaxosmithkline, LLC. | $55.28 | 2021-2024 | Trelegy Ellipta |
| Bayer Healthcare Pharmaceuticals INC. | $42.10 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $42.05 | 2023-2024 | Farxiga |
| Sanofi-Aventis U.S. LLC | $38.32 | 2024 | |
| Novartis Pharmaceuticals Corporation | $34.97 | 2023 | |
| Novo Nordisk INC | $32.77 | 2023-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $29.79 | 2023 | Trulicity, Jardiance |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $29.49 | 2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $25.93 | 2023 | Delstrigo, Dificid, Pifeltro |
| Amgen INC. | $23.72 | 2024 | Otezla, Repatha |
| Boston Scientific Corporation | $23.09 | 2024 | |
| Abbott Laboratories | $21.65 | 2025 | Freestyle Libre 3 |
| Impulse Dynamics (USA) INC. | $17.45 | 2024 | Optimizer |
| Teva Pharmaceuticals USA, INC. | $17.24 | 2024 | Uzedy |
| Recordati_rare_diseases_inc. | $16.55 | 2025 | Panhematin |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $16.32 | 2025 | Caplyta |
| Dexcom, INC. | $15.27 | 2023 | Dexcom G6 Transmitter |
| Inspire Medical Systems, INC. | $14.06 | 2024 | Inspire |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lalith Gande listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.